1. Brief research report: in-depth immunophenotyping reveals stability of CD19 CAR T-cells over time
- Author
-
Ivan Odak, Lâle M. Bayir, Lennart Riemann, Ruth Sikora, Jessica Schneider, Yankai Xiao, Nora Möhn, Thomas Skripuletz, Gernot Beutel, Matthias Eder, Arnold Ganser, Reinhold Förster, Christian R. Schultze-Florey, and Christian Koenecke
- Subjects
CAR T-cell ,DLBCL diffuse large B-cell lymphoma ,ALL acute lymphoblastic leukemia ,tisagenlecleucel tisa-cel ,spectral flow cytometry ,immunophenotyping ,Immunologic diseases. Allergy ,RC581-607 - Abstract
Variability or stability might have an impact on treatment success and toxicity of CD19 CAR T-cells. We conducted a prospective observational study of 12 patients treated with Tisagenlecleucel for CD19+ B-cell malignancies. Using a 31-color spectral flow cytometry panel, we analyzed differentiation stages and exhaustion markers of CAR T-cell subsets prior to CAR T-cell infusion and longitudinally during 6 months of follow-up. The majority of activation markers on CAR T-cells showed stable expression patterns over time and were not associated with response to therapy or toxicity. Unsupervised cluster analysis revealed an immune signature of CAR T-cell products associated with the development of immune cell-associated neurotoxicity syndrome. Warranting validation in an independent patient cohort, in-depth phenotyping of CAR T-cell products as well as longitudinal monitoring post cell transfer might become a valuable tool to increase efficacy and safety of CAR T-cell therapy.
- Published
- 2024
- Full Text
- View/download PDF